Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes
Yıl: 2021 Cilt: 31 Sayı: 2 Sayfa Aralığı: 157 - 164 Metin Dili: İngilizce DOI: 10.5152/pcp.2021.20161 İndeks Tarihi: 04-06-2023
Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes
Öz: Background: The brain extracellular matrix (ECM) is composed of glycoproteins deriving from the cell membrane and joining into nets called perineuronal nets (PNNs). The ECM glycoproteins limit neuroplasticity, cell proliferation, and differentiation. Electroconvulsive therapy (ECT) is provided by electrical currents that may alter several cascades and biophysical effects. ECM conformation might be influenced by the effects of ECT. Methods: Patients with depressive disorders (n = 23) and healthy control subjects (n = 21) were enrolled. Serum levels of the ECM glycoproteins versican, brevican, neurocan, phosphocan and tenascin C were measured with enzyme-linked immunosorbent assay. Serum samples were collected from the patients in the patient group at 3 time points: before ECT, 30 min after the first session, and 30 min after the seventh session. Results: There was a significant difference in tenascin C levels (P = .001) between the groups. No other significant difference was observed. Serum levels of the measured ECM glycoproteins and prolidase activity did not differ in the depression group after the administration of ECT. Conclusions: Our results did not support the claim suggesting a possible mechanism for modulation of ECM glycoproteins by ECT. Serum levels may not necessarily reflect conformational changes in the ECM. Further studies are needed to investigate the effects of ECT on ECM glycoproteins. Modulation of the ECM may provide a new window suggesting improvement in treatments.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Sinyor M, Rezmovitz J, Zaretsky A. Screen all for depression. BMJ. 2016;352;352i1617. [CrossRef]
- 2. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007;64(5):543-552. [CrossRef]
- 3. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8(1):2861. [CrossRef]
- 4. World Health Organization. The World Heath Report 2001: Mental Health: Now Understanding, New Hope. Geneva: W.H.O. Office of Publications; 2001.
- 5. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA. 2003;289(23):3135-3144. [CrossRef]
- 6. Daly EJ, Trivedi MH, Wisniewski SR, et al. Health-related quality of life in depression: a STAR*D report. Ann Clin Psychiatry. 2010;22(1):43-55.
- 7. Cuijpers P, Smit F. Excess mortality in depression: a meta-analysis of community studies. J Affect Disord. 2002;72(3):227-236. [CrossRef]
- 8. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists Clinical Practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087-1206. [CrossRef]
- 9. Canbek O, Menges OO, Atagun MI, Kutlar MT, Kurt E. Report on 3 years’ experience in electroconvulsive therapy in bakirkoy research and training hospital for psychiatric and neurological diseases: 2008-2010. J ECT. 2013;29(1):51-57. [CrossRef]
- 10. Atay ÖC, Bag S, Usta H, Çetinkaya E, Yanik M. Satisfaction and attitude of bipolar patients regarding electroconvulsive therapy: modified or unmodified. Nord J Psychiatry. 2020;74(2):131-137. [CrossRef]
- 11. Singh A, Kar SK. How electroconvulsive therapy works?: understanding the neurobiological mechanisms. Clin Psychopharmacol Neurosci . 2017;15(3):210-221. [CrossRef]
- 12. Guloksuz S, Rutten BP, Arts B, van Os J, Kenis G. The immune system and electroconvulsive therapy for depression. J ECT. 2014;30(2):132-137. [CrossRef]
- 13. Pelletier SJ, Cicchetti F. Cellular and molecular mechanisms of action of transcranial direct current stimulation: evidence from in vitro and in vivo models. Int J Neuropsychopharmacol. 2014;18(2). [CrossRef]
- 14. Giordano J, Bikson M, Kappenman ES, et al. Mechanisms and effects of transcranial direct current stimulation. Dose Response. 2017;15(1):1559325816685467. [CrossRef]
- 15. Zimmermann R, Schmitt H, Rotter A, et al. Transient increase of plasma concentrations of amyloid beta peptides after electroconvulsive therapy. Brain Stimul. 2012;5(1):25-29. [CrossRef]
- 16. Shibasaki C, Takebayashi M, Itagaki K, et al. Altered serum levels of matrix metalloproteinase-2, -9 in response to electroconvulsive therapy for mood disorders. Int J Neuropsychopharmacol. 2016;19(9). [CrossRef]
- 17. Phang JM, Donald SP, Pandhare J, Liu Y. The metabolism of proline, a stress substrate, modulates carcinogenic pathways. Amino Acids. 2008;35(4):681-690. [CrossRef]
- 18. Wilk P, Uehlein M, Kalms J, et al. Substrate specificity and reaction mechanism of human prolidase. FEBS Journal. 2017;284(17):2870-2885. [CrossRef]
- 19. Surazynski A, Miltyk W, Palka J, Phang JM. Prolidase- dependent regulation of collagen biosynthesis. Amino Acids. 2008;35(4):731-738. [CrossRef]
- 20. Ysrayl BB, Balasubramaniam M, Albert I, Villalta F, Pandhare J, Dash C. A novel role of prolidase in cocaine- mediated breach in the barrier of brain microvascular endothelial cells. Sci Rep. 2019;9(1):2567. [CrossRef]
- 21. Surazynski A, Donald SP, Cooper SK, et al. Extracellular matrix and HIF-1 signaling: the role of prolidase. Int J Cancer. 2008;122(6):1435-1440. [CrossRef]
- 22. Phang JM, Liu W, Zabirnyk O. Proline metabolism and microenvironmental stress. Annu Rev Nutr. 2010;30:441- 463. [CrossRef]
- 23. Aspberg A, Miura R, Bourdoulous S, et al. The C-type lectin domains of lecticans, a family of aggregating chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein interactions independent of carbohydrate moiety. Proc Natl Acad Sci USA. 1997;94(19):10116- 10121. [CrossRef]
- 24. Köppe G, Brückner G, Härtig W, Delpech B, Bigl V. Characterization of proteoglycan-containing perineuronal nets by enzymatic treatments of rat brain sections. Histochem J. 1997;29(1):11-20. [CrossRef]
- 25. Tanaka Y, Mizoguchi K. Influence of aging on chondroitin sulfate proteoglycan expression and neural stem/ progenitor cells in rat brain and improving effects of a herbal medicine, yokukansan. Neuroscience. 2009;164(3):1224-1234. [CrossRef]
- 26. Sethi MK, Zaia J. Extracellular matrix proteomics in schizophrenia and Alzheimer’s disease. Anal Bioanal Chem. 2017;409(2):379-394. [CrossRef]
- 27. Bach D, Brown SA, Kleim B, Tyagarajan S. Extracellular matrix: a new player in memory maintenance and psychiatric disorders. Swiss Med Wkly. 2019;149;149w20060. [CrossRef]
- 28. Chelini G, Pantazopoulos H, Durning P, Berretta S. The tetrapartite synapse: a key concept in the pathophysiology of schizophrenia. Eur Psychiatry. 2018;50:60-69. [CrossRef]
- 29. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol. 2011;209(2):139-151. [CrossRef]
- 30. Wight TN, Kang I, Merrilees MJ. Versican and the control of inflammation. Matrix Biol. 2014;35:152-161. [CrossRef]
- 31. Rauch U, Gao P, Janetzko A, et al. Isolation and characterization of developmentally regulated chondroitin sulfate and chondroitin/keratan sulfate proteoglycans of brain identified with monoclonal antibodies. J Biol Chem. 1991;266(22):14785-14801.
- 32. Mauney SA, Athanas KM, Pantazopoulos H, et al. Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. Biol Psychiatry. 2013;74(6):427-435. [CrossRef]
- 33. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch Gen Psychiatry. 2010;67(2):155- 166. [CrossRef]
- 34. Alcaide J, Guirado R, Crespo C, et al. Alterations of perineuronal nets in the dorsolateral prefrontal cortex of neuropsychiatric patients. Int J Bipolar Disord . 2019;7(1):24. [CrossRef]
- 35. Yu Z, Chen N, Hu D, et al. Decreased density of perineuronal net in prelimbic cortex is linked to depressive-like behavior in young-aged rats. Front Mol Neurosci. 2020;13;134. [CrossRef]
- 36. Soleman S, Filippov MA, Dityatev A, Wight TN, Fawcett JW. Targeting the neural extracellular matrix in neurological disorders. Neuroscience. 2013;253:194- 213. [CrossRef]
- 37. Sorg BA, Berretta S, Blacktop JM, et al. Casting a wide net: role of perineuronal nets in neural plasticity. J Neurosci. 2016;36(45):11459-11468. [CrossRef]
- 38. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. New York, USA: (SCID- I/P), Biometric Research, New York State Psychiatric Institute; 2002.
- 39. Özkürkçügil A, Aydemir Ö, Yıldız M, Esen Danacı A, Köroğlu E. DSM-IV Eksen I Bozuklukları İçin Yapılandırılmış Klinik Görüşmenin Türkçe’ye Uyarlaması ve Güvenilirlik Çalışması. İlaç Tedavi Derg. 1999;12(4):233-236.
- 40. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62. [CrossRef]
- 41. Akdemir A, ÖS, Dağ İ, et al. (HDDÖ)’nin geçerliği, güvenirliği ve klinikte kullanımı. Psychiatry Psychol Psychopharmacol. 1996;4:251-258.
- 42. Overall JE, Gorham D. The brief psychiatric rating scale. Psychol Rep. 1962;10:799-812. [CrossRef]
- 43. Canbek O, Ipekcıoglu D, Menges OO, et al. Comparison of propofol, etomidate, and thiopental in anesthesia for electroconvulsive therapy: a randomized, double-blind clinical trial. J ECT. 2015;31(2):91-97. [CrossRef]
- 44. Atagun M, Atay O, Balaban O, et al. Investigating the impact of the ECT on thiol-disulphide homeostasis in depressive disorders. Psychiatry Clin Psychopharmacol. 2020;30(2):136-143. [CrossRef]
- 45. Canbek O, Yuksel G, Atagun MI, et al. Geriatric ECT at a Turkish teaching hospital: a 5-year experience. J ECT. 2014;30(3):e28-e29. [CrossRef]
- 46. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: application to iminodipeptiduria. Clin Chim Acta. 1982;125(2):193-205. [CrossRef]
- 47. Calzia D, Panfoli I, Ravera S, et al. Structural modification of proteins by direct electric current from low voltage. J Biochem Mol Toxicol. 2009;23(5):309-317. [CrossRef]
- 48. Bekard I, Dunstan DE. Electric field induced changes in protein conformation. Soft Matter. 2014;10(3):431-437. [CrossRef]
- 49. Dyck SM, Karimi-Abdolrezaee S. Chondroitin sulfate proteoglycans: key modulators in the developing and pathologic central nervous system. Exp Neurol . 2015;269:169-187. [CrossRef]
- 50. Buss A, Pech K, Kakulas BA, et al. NG2 and phosphacan are present in the astroglial scar after human traumatic spinal cord injury. BMC Neurol. 2009;9:932. [CrossRef]
- 51. García-Alías G, Barkhuysen S, Buckle M, Fawcett JW. Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation. Nat Neurosci. 2009;12(9):1145-1151. [CrossRef]
- 52. Petrosyan HA, HunanyanAS, Alessi V, et al. Neutralization of inhibitory molecule NG2 improves synaptic transmission, retrograde transport, and locomotor function after spinal cord injury in adult rats. J Neurosci. 2013;33(9):4032-4043. [CrossRef]
- 53. Howell MD, Gottschall PE. Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment. Neuroscience. 2012;217:6-18. [CrossRef]
- 54. Kokacya MH, Bahceci B, Bahceci I, Dilek AR, Dokuyucu R. Prolidase activity and oxidative stress in patients with major depressive disorder. Psychiatr Danub. 2014;26(4):314-318.
- 55. Selek S, Altindag A, Saracoglu G, Celik H, Aksoy N. Prolidase activity and its diagnostic performance in bipolar disorder. J Affect Disord. 2011;129(1-3):84-86. [CrossRef]
- 56. Demir S, İbiloğlu AO, Güneş M, et al.Prolidase activity in major depressive disorder. J Clin Exp Investig. 2015;6:296-300. [CrossRef]
- 57. Demir S, Bulut M, Atli A, et al. Decreased prolidase activity in patients with posttraumatic stress disorder. Psychiatry Investig. 2016;13(4):420-426. [CrossRef]
- 58. Wilk P, Wator E, Weiss MS. Prolidase—a protein with many faces. Biochimie. 2021;183:3-12. [CrossRef]
| APA | canbek o, Atagün M, balaban ö, Ipekcioglu D, alpuğan b, Yalçın S, ŞENAT A, Karamustafalıoğlu N, İlnem M, EREL O (2021). Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. , 157 - 164. 10.5152/pcp.2021.20161 |
| Chicago | canbek ozge,Atagün Murat İlhan,balaban özlem devrim,Ipekcioglu Derya,alpuğan barış,Yalçın Suat,ŞENAT Almila,Karamustafalıoğlu Nesrin,İlnem Mehmet Cem,EREL Ozcan Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. (2021): 157 - 164. 10.5152/pcp.2021.20161 |
| MLA | canbek ozge,Atagün Murat İlhan,balaban özlem devrim,Ipekcioglu Derya,alpuğan barış,Yalçın Suat,ŞENAT Almila,Karamustafalıoğlu Nesrin,İlnem Mehmet Cem,EREL Ozcan Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. , 2021, ss.157 - 164. 10.5152/pcp.2021.20161 |
| AMA | canbek o,Atagün M,balaban ö,Ipekcioglu D,alpuğan b,Yalçın S,ŞENAT A,Karamustafalıoğlu N,İlnem M,EREL O Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. . 2021; 157 - 164. 10.5152/pcp.2021.20161 |
| Vancouver | canbek o,Atagün M,balaban ö,Ipekcioglu D,alpuğan b,Yalçın S,ŞENAT A,Karamustafalıoğlu N,İlnem M,EREL O Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. . 2021; 157 - 164. 10.5152/pcp.2021.20161 |
| IEEE | canbek o,Atagün M,balaban ö,Ipekcioglu D,alpuğan b,Yalçın S,ŞENAT A,Karamustafalıoğlu N,İlnem M,EREL O "Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes." , ss.157 - 164, 2021. 10.5152/pcp.2021.20161 |
| ISNAD | canbek, ozge vd. "Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes". (2021), 157-164. https://doi.org/10.5152/pcp.2021.20161 |
| APA | canbek o, Atagün M, balaban ö, Ipekcioglu D, alpuğan b, Yalçın S, ŞENAT A, Karamustafalıoğlu N, İlnem M, EREL O (2021). Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. Psychiatry and clinical psychopharmacology (Online), 31(2), 157 - 164. 10.5152/pcp.2021.20161 |
| Chicago | canbek ozge,Atagün Murat İlhan,balaban özlem devrim,Ipekcioglu Derya,alpuğan barış,Yalçın Suat,ŞENAT Almila,Karamustafalıoğlu Nesrin,İlnem Mehmet Cem,EREL Ozcan Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. Psychiatry and clinical psychopharmacology (Online) 31, no.2 (2021): 157 - 164. 10.5152/pcp.2021.20161 |
| MLA | canbek ozge,Atagün Murat İlhan,balaban özlem devrim,Ipekcioglu Derya,alpuğan barış,Yalçın Suat,ŞENAT Almila,Karamustafalıoğlu Nesrin,İlnem Mehmet Cem,EREL Ozcan Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. Psychiatry and clinical psychopharmacology (Online), vol.31, no.2, 2021, ss.157 - 164. 10.5152/pcp.2021.20161 |
| AMA | canbek o,Atagün M,balaban ö,Ipekcioglu D,alpuğan b,Yalçın S,ŞENAT A,Karamustafalıoğlu N,İlnem M,EREL O Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. Psychiatry and clinical psychopharmacology (Online). 2021; 31(2): 157 - 164. 10.5152/pcp.2021.20161 |
| Vancouver | canbek o,Atagün M,balaban ö,Ipekcioglu D,alpuğan b,Yalçın S,ŞENAT A,Karamustafalıoğlu N,İlnem M,EREL O Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes. Psychiatry and clinical psychopharmacology (Online). 2021; 31(2): 157 - 164. 10.5152/pcp.2021.20161 |
| IEEE | canbek o,Atagün M,balaban ö,Ipekcioglu D,alpuğan b,Yalçın S,ŞENAT A,Karamustafalıoğlu N,İlnem M,EREL O "Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes." Psychiatry and clinical psychopharmacology (Online), 31, ss.157 - 164, 2021. 10.5152/pcp.2021.20161 |
| ISNAD | canbek, ozge vd. "Electroconvulsive Therapy and Extracellular Matrix Glycoproteins in Patients with Depressive Episodes". Psychiatry and clinical psychopharmacology (Online) 31/2 (2021), 157-164. https://doi.org/10.5152/pcp.2021.20161 |
